Head to Head Comparison: BioCryst Pharmaceuticals (NASDAQ:BCRX) vs. BioForce Nanosciences (OTCMKTS:BFNH)

BioForce Nanosciences (OTCMKTS:BFNH) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

This table compares BioForce Nanosciences and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioForce Nanosciences	N/A	-84.67%	-16.36%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Earnings & Valuation

This table compares BioForce Nanosciences and BioCryst Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioForce Nanosciences	N/A	N/A	-$1.29 million	$0.01	384.00
BioCryst Pharmaceuticals	$874.84 million	2.83	$263.86 million	($1.50)	-6.47

BioCryst Pharmaceuticals has higher revenue and earnings than BioForce Nanosciences. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than BioForce Nanosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BioForce Nanosciences has a beta of -0.52, meaning that its stock price is 152% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.

Institutional & Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 39.5% of BioForce Nanosciences shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for BioForce Nanosciences and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioForce Nanosciences	0	0	0	0	0.00
BioCryst Pharmaceuticals	0	4	8	0	2.67

BioCryst Pharmaceuticals has a consensus target price of $20.60, indicating a potential upside of 112.37%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than BioForce Nanosciences.

Summary

BioCryst Pharmaceuticals beats BioForce Nanosciences on 8 of the 13 factors compared between the two stocks.

About BioForce Nanosciences

BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels. BioForce Nanosciences Holdings, Inc. is based in Virginia Beach, Virginia.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.